NCT03933488View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

March 29, 2020

Study Completion Date

March 29, 2020

Conditions
Healthy Participants
Interventions
DRUG

TAK-994

TAK-994 tablets.

DRUG

TAK-994 Placebo

TAK-994 placebo-matching tablets.

Trial Locations (2)

84125

PRA Health Sciences, Salt Lake City

91206

Parexel International, Glendale

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY